4016 Stock Overview
Engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 6/6 |
Financial Health | 5/6 |
Dividends | 2/6 |
Middle East Pharmaceutical Industries Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ر.س130.00 |
52 Week High | ر.س156.00 |
52 Week Low | ر.س107.00 |
Beta | 0 |
1 Month Change | -1.22% |
3 Month Change | -0.61% |
1 Year Change | -12.16% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 21.95% |
Recent News & Updates
Recent updates
Shareholder Returns
4016 | SA Pharmaceuticals | SA Market | |
---|---|---|---|
7D | 2.4% | 0.9% | 1.6% |
1Y | -12.2% | 4.2% | -11.9% |
Return vs Industry: 4016 underperformed the SA Pharmaceuticals industry which returned 4.2% over the past year.
Return vs Market: 4016 matched the SA Market which returned -11.9% over the past year.
Price Volatility
4016 volatility | |
---|---|
4016 Average Weekly Movement | 4.2% |
Pharmaceuticals Industry Average Movement | 6.2% |
Market Average Movement | 5.0% |
10% most volatile stocks in SA Market | 7.6% |
10% least volatile stocks in SA Market | 3.2% |
Stable Share Price: 4016 has not had significant price volatility in the past 3 months compared to the SA market.
Volatility Over Time: 4016's weekly volatility (4%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 632 | Mohammed Maher Al-Ghannam | www.avalonpharmaceutical.com |
Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. It offers medicines and preparations used to treat skin diseases, skin creams, and skin care products; respiratory, central nervous, digestive, and musculoskeletal system medicines; urinary and reproductive system drugs; disinfectants; and various therapeutic medicines and preparations, including sexual system drugs, diabetes, cardiovascular drugs, anti-infective drugs, anti-parasitic drugs, pain relievers, antiseptics, and women’s and men’s health drugs in the form of creams, rolls, ointments, syrups, masks, tonics, lotions, capsules, gels, hand sanitizers, mouthwashes, soaps, solutions, sprays, scrubs, topical solutions, and tablets.
Middle East Pharmaceutical Industries Company Fundamentals Summary
4016 fundamental statistics | |
---|---|
Market cap | ر.س2.60b |
Earnings (TTM) | ر.س79.85m |
Revenue (TTM) | ر.س394.00m |
32.6x
P/E Ratio6.6x
P/S RatioIs 4016 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4016 income statement (TTM) | |
---|---|
Revenue | ر.س394.00m |
Cost of Revenue | ر.س151.59m |
Gross Profit | ر.س242.41m |
Other Expenses | ر.س162.56m |
Earnings | ر.س79.85m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 3.99 |
Gross Margin | 61.52% |
Net Profit Margin | 20.27% |
Debt/Equity Ratio | 17.8% |
How did 4016 perform over the long term?
See historical performance and comparisonDividends
1.9%
Current Dividend Yield50%
Payout RatioDoes 4016 pay a reliable dividends?
See 4016 dividend history and benchmarksMiddle East Pharmaceutical Industries dividend dates | |
---|---|
Ex Dividend Date | May 04 2025 |
Dividend Pay Date | May 15 2025 |
Days until Ex dividend | 4 days |
Days until Dividend pay date | 15 days |
Does 4016 pay a reliable dividends?
See 4016 dividend history and benchmarksCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/04/29 20:48 |
End of Day Share Price | 2025/04/29 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Middle East Pharmaceutical Industries Company is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Madhu Appissa | Al Rajhi Capital |
null null | SNB Capital |